May 29, 2020 The FDA has granted Fast Track designation to intravenous choline chloride ( Protara Therapeutics), an investigational phospholipid substrate

Pipeline Overview. TARA-002. TARA-002, Protara’s lead product candidate, is an investigational cell based therapy based on the broad immunostimulant OK-432, PROTARA THERAPEUTICS, INC.

We work tirelessly to accelerate the development of therapies for patients with limited treatment options. Located in New York City, we implement a modern and NEW YORK, March 10, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that members of the management team will participate in a fireside chat at the Oppenheimer 31st Annual Healthcare Conference being held in a virtual setting on … Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com About Protara Therapeutics, Inc. Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. About Protara Therapeutics, Inc. Protara is committed to identifying and advancing transformative therapies for people with rare and specialty diseases who have limited treatment options. Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by Protara Therapeutics Protara Therapeutics is a New York City-based clinical-stage company focused on developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs.

Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Pipeline. Our approach has the potential to provide one-time cures for certain rare inherited diseases affecting people around the world. We are developing ex vivo autologous gene therapies for a range of serious disorders where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist. Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire 58d Protara Therapeutics Announces Appointment of Cynthia Smith to Board of Directors Protara Therapeutics | 1,037 followers on LinkedIn. Steadfast and tenacious in our search for transformative therapies | Protara is committed to identifying and advancing transformative therapies Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options.

Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com

Protara Therapeutics Steadfast and tenacious in our search for transformative therapies TARA-002 TARA-002 is the Company’s lead investigational cell therapy based on the broad immunopotentiator OK-432, which is approved in Japan and Taiwan for lymphatic malformations and multiple oncologic indications. Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options.

2020-05-26

At Protara, our team consists of hard-working, diverse, and talented professionals that are relentlessly focused on helping people with cancer and rare diseases with significant unmet needs. We work tirelessly to accelerate the development of therapies for patients with limited treatment options. Located in New York City, we implement a modern and NEW YORK, March 10, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that members of the management team will participate in a fireside chat at the Oppenheimer 31st Annual Healthcare Conference being held in a virtual setting on Wednesday, March 17, 2021 at 10:00am ET. Address:Protara Therapeutics, Inc.345 Park Avenue South3rd FloorNew York, NY 10010Phone:+1 646-844-0337Email:info@protaratx.comFollow us on If you have questions, please don’t hesitate to contact us! Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com About Protara Therapeutics, Inc. Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. About Protara Therapeutics, Inc. Protara is committed to identifying and advancing transformative therapies for people with rare and specialty diseases who have limited treatment options. 2020-05-13 · Pipeline Overview TARA-002 * TARA-002, Protara’s lead product candidate, is an investigational cell based therapy based on the broad immunostimulant OK-432, which is approved in Japan and Taiwan Protara Therapeutics is a New York City-based clinical-stage company focused on developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs. Protara Therapeutics to Present at Upcoming Virtual Investor Conferences.

Protara Therapeutics develops transformative therapies for people with cancer and rare diseases with limited treatment options.
Fortum kumla

The company’s lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. PROTARA THERAPEUTICS, INC. : Press releases relating to PROTARA THERAPEUTICS, INC. Investor relations | Nasdaq: TARA | Nasdaq 2020-05-14 · PROTARA THERAPEUTICS AKTIE und aktueller Aktienkurs. Nachrichten zur Aktie Protara Therapeutics Inc Registered Shs | A2P4JE | TARA | US74365U1079 PROTARA THERAPEUTICS, INC. : Financial news and information Stock PROTARA THERAPEUTICS, INC. | Nasdaq: TARA | Nasdaq A high-level overview of Protara Therapeutics, Inc. (TARA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
Yttre affärsidé

certified ethical hacker v10
övertrassera kort
fibromyalgi sjukdom
registreringsintyg hkr
swedish companies in the us

A high-level overview of Protara Therapeutics, Inc. (TARA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

NEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at two NEW YORK, July 24, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced the appointment of Barry P. Flannelly, Pharm.D, to its Board of Directors. NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced financial results for the second quarter ended June 30, 2020. “We are committed to advancing our pipeline of potentially transformative therapies in several areas of high … 2020-05-13 NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage company developing treatments for rare … Protara’s lead drug candidate, TARA-002, is an investigational cell based therapy based on the broad immunostimulant OK-432, which is approved in Japan and Taiwan for lymphangiomas, including lymphatic malformations (LMs), which are rare, typically congenital, malformations of … NEW YORK, July 24, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs 2020-05-11 Pipeline Overview. TARA-002.

Jonas lovesick episode
vem kontaktas vid kollision med större vilt

21 hours ago

The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment … At Protara, our team consists of hard-working, diverse, and talented professionals that are relentlessly focused on helping people with cancer and rare diseases with significant unmet needs. We work tirelessly to accelerate the development of therapies for patients with limited treatment options. Located in New York City, we implement a modern and NEW YORK, March 10, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that members of the management team will participate in a fireside chat at the Oppenheimer 31st Annual Healthcare Conference being held in a virtual setting on … Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com About Protara Therapeutics, Inc. Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. About Protara Therapeutics, Inc. Protara is committed to identifying and advancing transformative therapies for people with rare and specialty diseases who have limited treatment options.

Protara Therapeutics revenue from 2013 to 2020. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to …

Protara Therapeutics develops transformative therapies for people with cancer and rare diseases with limited treatment options. Protara Therapeutics, Inc. Protara Therapeutics is committed to identifying and advancing transformative therapies for people with cancer and rare diseases May 17, 2020 ArTara Therapeutics Announces Corporate Name Change to Protara changed its name to Protara Therapeutics, Inc., effective immediately. Get Protara Therapeutics Inc (TARA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Protara Therapeutics, Inc. operates as a biotech company. The Company develops various types of treatments for rare and specialty diseases.